Frontlight ResearchEarly access
Spinal muscular atrophy trials in Italy
5 of 9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- Where
- Milan, Rome
- Age
- Up to 17 years
- People
- 30 worldwide
- Run by
- Scholar Rock Inc.
See details and how to join2024-520130-29-00 - Phase 3Not yet taking people in ItalyA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Where
- Milan
- Age
- 0 days to 42 days
- People
- 30 worldwide
- Run by
- Biogen
See details and how to joinNCT07221669 · EU 2025-524054-34-00 - Phase 3Not yet taking people in ItalyA Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
- Where
- Milan, Rome
- Age
- 0 days to 7 months
- People
- 42 worldwide
- Run by
- Biogen
See details and how to joinNCT07444450 · EU 2025-523857-32-00 - Phase 2Taking peopleA Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- Where
- Milan, Rome
- Age
- Up to 2 years
- People
- 52 worldwide
- Run by
- Scholar Rock, Inc.
See details and how to joinNCT07047144 - Phase 1CompletedA Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
- Where
- Milan, Rome
- Age
- 3 years and over
- People
- 78 worldwide
- Run by
- Biogen
See details and how to joinNCT06555419 · EU 2024-514239-21-00